# Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

> **NCT01652092** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 57 (actual)

## Conditions studied

- SCID
- Omenn's Syndrome
- Reticular Dysgenesis
- Wiskott-Aldrich Syndrome
- Bare Lymphocyte Syndrome
- Common Variable Immunodeficiency
- Chronic Granulomatous Disease
- CD40 Ligand Deficiency
- Hyper IgM Syndrome
- X-linked Lymphoproliferative Disease
- Hemophagocytic Lymphohistiocytosis
- Griscelli Syndrome
- Chediak-Higashi Syndrome
- Langerhan's Cell Histiocytosis

## Interventions

- **DRUG:** Alemtuzumab 0.3 mg
- **DRUG:** Cyclophosphamide
- **DRUG:** Busulfan
- **BIOLOGICAL:** Stem Cell Transplantation
- **DRUG:** Fludarabine phosphate 40 mg
- **DRUG:** Melphalan
- **DRUG:** Alemtuzumab 0.2 mg
- **DRUG:** Busulfan
- **DRUG:** Fludarabine phosphate 30 mg
- **DRUG:** MESNA

## Key facts

- **NCT ID:** NCT01652092
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-09-04
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01652092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01652092, "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01652092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*